Pasithea to Unveil First PAS-004 NF1 Clinical Data at European Conference
KTTA sits 96% above its 52-week low of $0.281 on light trading volume (0.2× avg).
Summary
Pasithea will present initial Part A data from its Phase 1/1b trial of PAS-004 in adult NF1 patients at the European Neurofibromatosis Conference in Vienna, November 12-14. This is the first public disclosure of clinical data from this trial, with an oral presentation on cutaneous neurofibromas and a poster on plexiform neurofibromas. The company plans to issue a detailed results press release at the time of presentation. This follows positive interim Phase 1 data in advanced cancer patients reported in June, and the recent shareholder approval of a reverse stock split to address Nasdaq listing requirements. The upcoming data could validate PAS-004's potential in NF1, a significant unmet need, and may influence the company's financing and partnership prospects.
At the time of this announcement, KTTA was trading at $0.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $17.7M. The 52-week trading range was $0.28 to $2.06. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.